Inhibikase Therapeutics (IKT) Assets Average (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Assets Average data on file, last reported at $177.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 83.81% year-over-year to $177.3 million in Q1 2026; TTM through Mar 2026 was $177.3 million, a 83.81% increase from a year earlier, with the FY2025 full-year figure at $139.9 million, up 147.38% from the prior year.
• Assets Average for Q1 2026 stood at $177.3 million, up from $130.4 million in the prior quarter.
• Over the last five years, Assets Average for IKT reached as high as $177.3 million in Q1 2026 and fell as low as $6.6 million in Q3 2024.
• Historically, Assets Average has averaged $52.0 million across 5 years, with a median of $31.3 million in 2022.
• Across the five-year window, Assets Average sank 67.18% in 2024 and surged 1175.76% in 2025, its largest moves.
• Year by year, Assets Average stood at $26.8 million in 2022, then plunged by 39.48% to $16.2 million in 2023, then surged by 217.95% to $51.5 million in 2024, then jumped by 153.26% to $130.4 million in 2025, then jumped by 35.94% to $177.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $177.3 million in Q1 2026, $130.4 million in Q4 2025, and $84.2 million in Q3 2025.